カテゴリ： GlobalData, アメリカ, 企業調査

Spectrum Pharmaceuticals Inc (SPPI)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Spectrum Pharmaceuticals Inc (SPPI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013914
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：70
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Spectrum Pharmaceuticals Inc (Spectrum) is a biotechnology company that develops and commercializes a pipeline of late-stage clinical and commercial products with focus on hematology and oncology. The company’s marketed drugs include Fusilev (levoleucovorin); Folotyn (pralatrexate injection); Zevalin (ibritumomab tiuxetan); Marqibo (vincristine sulfate liposome injection), Beleodaq (belinostat) and Evomela (Captisol-Enabled Melphalan). It also has drugs in mid-to-late stage development, namely, Rolontis (eflapegrastim) for chemotherapy-induced neutropenia; Qapzola (apaziquone) for Intravesical Instillation; and Poziotinib for the treatment of various types of cancers. The company markets its products through direct sales force in the US and through distributors in Europe. Spectrum is headquartered in Henderson, Nevada, the US.

Spectrum Pharmaceuticals Inc (SPPI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Allos Therapeutics Enters Into Collaboration And Licensing Agreement With Mundipharma International For FOLOTYN 13
myTomorrows Enters into Agreement with Spectrum Pharma 15
Spectrum Pharma Enters into Agreement with Servier Canada 16
Eagle Pharma Enters into Agreement with Spectrum Pharma 17
Licensing Agreements 18
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 18
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 19
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 20
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 21
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 22
Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 23
Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 25
Spectrum Pharma Amends Licensing Agreement With TopoTarget For Belinostat 26
Allos Therapeutics Amends Licensing Agreement With Mundipharma International For Folotyn 27
Spectrum Pharma Enters Into Licensing Agreement With Bayer Healthcare For Zevalin 28
Viropro Enters Into Licensing Agreement With Spectrum Pharma For Rituximab 30
Equity Offering 31
Spectrum Pharma Plans to Raise up to USD150 Million in Private Placement of Shares 31
Spectrum Pharma Raises USD3 Million in Private Placement of Shares 32
Talon Therapeutics Completes Private Placement Of Preferred Stock For US$11 Million 33
Spectrum Pharma Completes Private Placement Of Shares For US$25 Million Upon Exercise Of Warrants 35
Debt Offering 36
Spectrum Pharma Completes Private Placement Of Notes Due 2018 For US$100 Million 36
Acquisition 38
Spectrum Pharma Acquires Majority Stake In Talon Therapeutics 38
Spectrum Pharma Completes Acquisition Of Allos Therapeutics For US$206 Million 40
Spectrum Pharmaceuticals Inc – Key Competitors 42
Spectrum Pharmaceuticals Inc – Key Employees 43
Spectrum Pharmaceuticals Inc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 45
Recent Developments 46
Financial Announcements 46
Nov 02, 2017: Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update 46
Aug 03, 2017: Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update 48
May 02, 2017: Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update 49
Mar 08, 2017: Spectrum Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results and Pipeline Update 50
Nov 14, 2016: Spectrum Pharmaceuticals Provides Third Quarter Financial Update 52
Nov 03, 2016: Spectrum Pharmaceuticals Provides Third Quarter Financial and Pipeline Update 53
Aug 09, 2016: Spectrum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Pipeline Update 54
May 05, 2016: Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results and Pipeline Update 55
Mar 09, 2016: Spectrum Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results and Pipeline Update 56
Product News 58
12/06/2016: Spectrum Pharmaceuticals Highlights Survival Advantage in a Case Match Control Analysis of the PROPEL Study with FOLOTYN (pralatrexate injection) at the 58th Annual Meeting of the American Society of Hematology 58
12/05/2016: CASI Pharmaceuticals’ Import Drug Registration Application For EVOMELA Accepted For Review By CFDA 59
12/02/2016: Spectrum Pharmaceuticals Announces Key Presentations at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, December 3-6, 2016 60
12/02/2016: Spectrum Pharmaceuticals Highlights Abstracts on ZEVALIN (ibritumomab tiuxetan) at the 58th Annual Meeting of the American Society of Hematology in San Diego, California, December 3-6, 2016 61
09/14/2016: FDA Advisory Committee Votes that Qapzola (apaziquone) Has Not Shown Substantial Evidence of a Treatment Effect Over Placebo 62
06/02/2017: Spectrum Pharmaceuticals Highlights Clinical Data on FOLOTYN at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017 63
Product Approvals 64
Nov 17, 2016: Spectrum Pharmaceuticals Receives Complete Response Letter From the FDA for QAPZOLA 64
Apr 20, 2016: FDA Grants Orphan Drug Exclusivity to EVOMELA (melphalan) for Injection, Indicated for Multiple Myeloma 65
Mar 15, 2016: FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA (melphalan) for Injection 66
Feb 19, 2016: Spectrum Pharmaceuticals Announces FDA Acceptance of NDA Filing for EOquin (apaziquone for intravesical instillation) 67
Clinical Trials 68
Jun 19, 2017: Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting 68
May 06, 2016: Spectrum Pharmaceuticals Highlights an Oral Presentation on Apaziquone at the 2016 Annual Meeting of the American Urological Association Education and Research (AUA) in San Diego, California, May 6-10, 2016 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70

List of Tables
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Spectrum Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Allos Therapeutics Enters Into Collaboration And Licensing Agreement With Mundipharma International For FOLOTYN 13
myTomorrows Enters into Agreement with Spectrum Pharma 15
Spectrum Pharma Enters into Agreement with Servier Canada 16
Eagle Pharma Enters into Agreement with Spectrum Pharma 17
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 18
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 19
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 20
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 21
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 22
Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 23
Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 25
Spectrum Pharma Amends Licensing Agreement With TopoTarget For Belinostat 26
Allos Therapeutics Amends Licensing Agreement With Mundipharma International For Folotyn 27
Spectrum Pharma Enters Into Licensing Agreement With Bayer Healthcare For Zevalin 28
Viropro Enters Into Licensing Agreement With Spectrum Pharma For Rituximab 30
Spectrum Pharma Plans to Raise up to USD150 Million in Private Placement of Shares 31
Spectrum Pharma Raises USD3 Million in Private Placement of Shares 32
Talon Therapeutics Completes Private Placement Of Preferred Stock For US$11 Million 33
Spectrum Pharma Completes Private Placement Of Shares For US$25 Million Upon Exercise Of Warrants 35
Spectrum Pharma Completes Private Placement Of Notes Due 2018 For US$100 Million 36
Spectrum Pharma Acquires Majority Stake In Talon Therapeutics 38
Spectrum Pharma Completes Acquisition Of Allos Therapeutics For US$206 Million 40
Spectrum Pharmaceuticals Inc, Key Competitors 42
Spectrum Pharmaceuticals Inc, Key Employees 43
Spectrum Pharmaceuticals Inc, Other Locations 44
Spectrum Pharmaceuticals Inc, Subsidiaries 44
Spectrum Pharmaceuticals Inc, Joint Venture 45

★海外企業調査レポート[Spectrum Pharmaceuticals Inc (SPPI)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Ann Inc：企業の戦略的SWOT分析
    Ann Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Whole Foods Market Inc：企業の戦略・SWOT・財務情報
    Whole Foods Market Inc - Strategy, SWOT and Corporate Finance Report Summary Whole Foods Market Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • HSBC Trinkaus & Burkhardt Private Banking：企業の戦略・SWOT・財務情報
    HSBC Trinkaus & Burkhardt Private Banking - Strategy, SWOT and Corporate Finance Report Summary HSBC Trinkaus & Burkhardt Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Houston American Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    Houston American Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary Houston American Energy Corp (Houston American Energy) is an oil and gas company that provides exploration and development services. The company concentrates on development, exploration, …
  • Oakton Limited：企業の戦略的SWOT分析
    Oakton Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Cardinal Ethanol LLC：企業の戦略的SWOT分析
    Cardinal Ethanol LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Cytori Therapeutics Inc (CYTX)-医療機器分野：企業M&A・提携分析
    Summary Cytori Therapeutics Inc (Cytori) is a clinical stage regenerative medicine company. It develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) for the treatment of cardiovascular disease, orthopedic conditions and gastrointestinal disorders. The company has two …
  • Advanced Accelerator Applications SA (AAAP)-製薬・医療分野：企業M&A・提携分析
    Summary Advanced Accelerator Applications SA (AAA) is a healthcare products provider that offers molecular nuclear medicine and diagnostic and therapeutic products. The company’s lead product candidate comprises Lutathera, a lutetium-177 somatostatin analogue peptide that is used for the treatment o …
  • Thai Airways International Public Co Ltd：企業の戦略・SWOT・財務分析
    Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Scripps Health-製薬・医療分野：企業M&A・提携分析
    Summary Scripps Health (Scripps) is a non-profit healthcare organization, which provides healthcare services including primary care and urgent and emergency care services; preventive services and wellness screening services in San Diego County in the US. Scripps offers specialized medical care with …
  • Bashneft (BANE)：企業の財務・戦略的SWOT分析
    Bashneft (BANE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • 23andMe Inc-医療機器分野：企業M&A・提携分析
    Summary 23andMe Inc (23andMe) is a biotechnology research and information provider that offers tools for health and ancestry care. The company offers raw genetic data and ancestry-related genetic reports. It offers clinical development, research and development, ancestry services, commercialization …
  • Takenaka Corporation：企業の戦略・SWOT・財務情報
    Takenaka Corporation - Strategy, SWOT and Corporate Finance Report Summary Takenaka Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • InterOil Exploration & Production ASA Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    InterOil Exploration & Production ASA Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary InterOil Exploration & Production ASA (InterOil Exploration & Production) is an oil and gas company that provides petroleum exploration services. The company acquires, explores, …
  • Harbin Pharmaceutical Group Co Ltd (600664)：企業の財務・戦略的SWOT分析
    Harbin Pharmaceutical Group Co Ltd (600664) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Medical Prognosis Institute AS (MPI)-医療機器分野：企業M&A・提携分析
    Summary Medical Prognosis Institute A/S (MPI) is a precision medicine provider that offers cancer treatment solutions. The company offers DRP platforms that provide tools for rationalized drug development and personalized medicine. It offers lead compound selection, drug rescue repositioning repurpo …
  • G-III Apparel Group, Ltd.：企業の戦略・SWOT・財務情報
    G-III Apparel Group, Ltd. - Strategy, SWOT and Corporate Finance Report Summary G-III Apparel Group, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Baron Oil Plc (BOIL)：企業の財務・戦略的SWOT分析
    Summary Baron Oil Plc (Baron Oil), formerly Gold Oil PLC is an oil and gas exploration and production company. The company identifies and develops crude oil and natural gas interests in Latin America including Peru and Colombia. It also holds working interests of Nancy Burdine Maxine oil field, oil …
  • Huawei Investment & Holding Co., Ltd.：企業の戦略・SWOT・財務情報
    Huawei Investment & Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Huawei Investment & Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • General Motors Co (GM)：企業の財務・戦略的SWOT分析
    General Motors Co (GM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆